<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03981822</url>
  </required_header>
  <id_info>
    <org_study_id>VP-102-104</org_study_id>
    <nct_id>NCT03981822</nct_id>
  </id_info>
  <brief_title>A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts</brief_title>
  <acronym>CARE-1</acronym>
  <official_title>A Phase 2, Double-Blind, Placebo-Controlled Study to Determine the Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects With External Genital Warts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Verrica Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instat Consulting, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Paidion Research, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>BioClinica, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Verrica Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, double-blind, placebo-controlled study to determine the dose regimen,&#xD;
      safety, tolerability, and efficacy of VP-102 in subjects with External Genital Warts (EGW).&#xD;
      This study is divided into two parts (Part A and Part B). Increasing durations of skin&#xD;
      exposure to study drug (VP-102 or placebo) will be evaluated in three treatment groups prior&#xD;
      to progressing to enrollment in Part B. Part A &amp; B will enroll a approximately 108 subjects&#xD;
      completing 4 treatment applications every 21 days and continuing with follow-up assessments&#xD;
      at Day 84, 112 and 147.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is to determine the Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in&#xD;
      Subjects with External Genital Warts. It is divided into two parts (Part A and Part B). The&#xD;
      aim of Part A is to determine the two best treatment regimens for evaluation of safety and&#xD;
      efficacy in Part B.In Part A, Study drug (VP-102 or placebo) will be administered once every&#xD;
      21 days for up to four applications. Enrollment will begin in Group 1, then proceed into&#xD;
      Group 2, and lastly into Group 3. A safety review will be conducted to determine whether&#xD;
      enrollment can be initiated into the next Group. An additional blinded safety review will be&#xD;
      performed after all six subjects in Group 3 have completed the 48-hour Visit, in order to&#xD;
      support dose selection for Part B (Safety and Efficacy). Part B of the study will begin&#xD;
      enrollment only after the Sponsor has selected the two dose regimens from Part A. The study&#xD;
      will remain blinded until completion of both parts of the study.&#xD;
&#xD;
      In Part A, up to 18 subjects will be randomized to VP-102 or placebo treatment with three&#xD;
      different regimens. When Part B is open an additional ~90 subjects will be enrolled and&#xD;
      randomized to VP-102 or placebo with two treatment regimens. Two of the treatment arms will&#xD;
      be VP-102 Regimen 1 and VP-102 Regimen 2. The other two treatment arms will be placebo&#xD;
      (Placebo Regimen 1 and Placebo Regimen 2), with corresponding durations of skin exposure&#xD;
      matching those selected for VP-102 Regimen 1 and Regimen 2. As an example, if the regimens&#xD;
      selected from Part A are the 2-hour and 6-hour applications of VP-102, then VP-102 Regimen 1&#xD;
      would be VP-102 treatment for 2-hours and VP-102 Regimen 2 would be VP-102 treatment for&#xD;
      6-hours. Likewise, Placebo Regimen 1 would be placebo treatment for 2 hours and Placebo&#xD;
      Regimen 2 would be placebo treatment for 6-hours. Randomization of the four treatment arms&#xD;
      (VP-102 Regimen 1:VP-102 Regimen 2:Placebo Regimen 1:Placebo Regimen 2) will be 3:3:2:2. In&#xD;
      both Regimen 1 and Regimen 2, study drug will be administered to EGW once every 21 days for&#xD;
      up to four applications. Subjects will be asked to remove the study drug at the designated&#xD;
      time selected from the dose regimen findings in Part A of the study. Treatment will continue&#xD;
      with a minimum of every 21 days, until complete clearance or a maximum of four treatment&#xD;
      sessions. Safety assessments including recording of local skin reactions are conducted at&#xD;
      each treatment visit and at follow up visits Day 84, 112, and 147.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 25, 2019</start_date>
  <completion_date type="Actual">July 8, 2020</completion_date>
  <primary_completion_date type="Actual">May 21, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The aim of Part A is to determine the two best treatment regimens for evaluation of safety and efficacy in Part B. Increasing durations of skin exposure to study drug (VP-102 or placebo) will be evaluated in three treatment groups (n=6/group) that will enroll progressively.&#xD;
Part B of the study will begin enrollment only after the Sponsor has selected the two dose regimens in Part A, which will be called VP-102 Regimen 1 and Regimen 2.Approximately 90 subjects will be enrolled and randomized to one of four treatment arms (two treatment regimens, each with VP-102 and Placebo). Randomization will be stratified by sex so that neither gender exceeds ~60% of any treatment arm. Two of the treatment arms will be VP-102 Regimen 1 and VP-102 Regimen 2. The other two treatment arms will be placebo (Placebo Regimen 1 and Placebo Regimen 2), with corresponding durations of skin exposure matching those selected for VP-102 Regimen 1 and Regimen 2.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts at the Study Day 84 (End of Treatment) Visit.</measure>
    <time_frame>Compares baseline wart count to Day 84, end of treatment.</time_frame>
    <description>Proportion of subjects exhibiting complete clearance of all treatable warts (baseline and new) at the Study Day 84 EOT Visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)</measure>
    <time_frame>Clearance compared from baseline to each study visit, treatment 2 (Day 21), 3 (Day 42), 4 (Day 63) and Day 84, 112 and 147.</time_frame>
    <description>Proportion of subjects exhibiting complete clearance of all treatable warts (baseline and new) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, and Follow-up Visits on Study Day 112 and Study Day 147 (EOS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects Exhibiting 90% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)</measure>
    <time_frame>Compared from baseline to each study visit, treatment 2 (Day 21), 3 (Day 42), 4 (Day 63) and Day 84, 112 and 147.</time_frame>
    <description>Proportion of subjects exhibiting 90% clearance of all treatable warts (baseline and new) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects Exhibiting 75% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)</measure>
    <time_frame>Compared from baseline to each study visit, treatment 2, (Day 21), 3 (Day 42), 4 (Day 63) and Day 84, 112 and 147.</time_frame>
    <description>Proportion of subjects exhibiting 75% clearance of all treatable warts (baseline and new) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)</measure>
    <time_frame>Compared from baseline to each study visit, treatment 2 (Day 21), 3 (Day 42), 4 (Day 63) and Day 84, 112 and 147.</time_frame>
    <description>Change from baseline in the number of treatable warts (baseline and new) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS).&#xD;
Number of warts present were recorded at each treatment visit as well as follow-up visits. For each post baseline treatment visit, the change in number of warts from baseline was calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)</measure>
    <time_frame>Percent change from baseline to each study visit, treatment 2 (Day 21), 3 (Day 42), 4 (Day 63) and Day 84, 112 and 147.</time_frame>
    <description>Percent Change from Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)</measure>
    <time_frame>Compared from baseline to each study visit, treatment 2 (Day 21), 3 (Day 42), 4 (Day 63) and Day 84, 112 and 147.</time_frame>
    <description>Proportion of subjects exhibiting reduction of ≥ 1 treatable wart from baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS).</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of Subjects Who Are Clear at the Study Day 84 (End of Treatment) Visit and Remain Clear at the Follow-up Visits on Study Day 112 and Study Day 147 (End of Study)</measure>
    <time_frame>Complete clearance compared from Day 84 to follow-up days 112 and 147.</time_frame>
    <description>Proportion of subjects who are clear at all three study visits, Study Day 84 (End of Treatment) Visit and remain clear at the Follow-up Visits on Study Day 112 and Study Day 147 (End of Study).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in Total Wart Area (Sum of Individual Warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)</measure>
    <time_frame>Baseline to Study Day 84, Follow-up Visits at Days 112 and 147 (EOS)</time_frame>
    <description>Change from baseline in total wart area (sum of individual warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS).</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change From Baseline in the Total Wart Area (Sum of Individual Warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)</measure>
    <time_frame>Baseline to Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)</time_frame>
    <description>Percent Change from baseline in the total wart area (sum of individual warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS).</description>
  </other_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Condylomata Acuminata</condition>
  <condition>Papillomavirus Infections</condition>
  <condition>Skin Diseases, Viral</condition>
  <condition>Skin Diseases, Infectious</condition>
  <condition>Skin Diseases</condition>
  <condition>Sexually Transmitted Diseases, Viral</condition>
  <condition>Sexually Transmitted Diseases</condition>
  <condition>Warts</condition>
  <arm_group>
    <arm_group_label>Part A: VP-102 2 hour-Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>For part A, VP-102 will be applied for 2 hours and removed. If selected as a dose regimen for Part B VP-102 will be applied for 2 hours and removed.In both parts, VP-102 is applied every 21 days for 4 treatments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: VP-102 6-hour Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>For part A, VP-102 will be applied for 6 hours and removed. If selected as a dose regimen for Part B VP-102 will be applied for 6 hours and removed. In both parts, VP-102 is applied every 21 days for 4 treatments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: VP-102 24-hour Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>For part A, VP-102 will be applied for 24 hours and removed. If selected as a dose regimen for Part B, VP-102 will be applied for 24 hours and removed. In both parts, VP-102 is applied every 21 days for 4 treatments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>For part A, VP-102 will be applied for 2-,6- or 24- hours and removed. Placebo is applied every 21 days for 4 treatments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B &amp; A: VP-102 6 hour-Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Part B, VP-102 will be applied for 6 hours and removed. VP-102 is applied every 21 days for 4 treatments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B &amp; A: 6-hour-Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Part B, Placebo will be applied for 6 hours and removed. VP-102 is applied every 21 days for 4 treatments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B &amp; A: VP-102 24-hour Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>For part A, VP-102 will be applied for 24 hours and removed. If 24 hours is selected as a dose regimen for Part B, VP-102 will be applied for 24 hours and removed. VP-102 is applied every 21 days for 4 treatments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B &amp; A: 24-hour-Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Part B, VP-Placebo will be applied for 24 hours and removed. VP-102 is applied every 21 days for 4 treatments.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>VP-102 and applicator</intervention_name>
    <description>In part A, VP-102 will be applied for either 2, 6 or 24 hours with each regimen compared to placebo. For part B, 2 of the regimens from part A will be chosen for Part B with each compared to Placebo. Only 4 arms are actually being studied.</description>
    <arm_group_label>Part A: VP-102 2 hour-Active</arm_group_label>
    <arm_group_label>Part A: VP-102 24-hour Active</arm_group_label>
    <arm_group_label>Part A: VP-102 6-hour Active</arm_group_label>
    <arm_group_label>Part B &amp; A: VP-102 24-hour Active</arm_group_label>
    <arm_group_label>Part B &amp; A: VP-102 6 hour-Active</arm_group_label>
    <other_name>VP-102 (cantharidin) 0.7% w/v topical solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo single-use applicator contains the same formulation as the VP-102 applicator but does not contain the active pharmaceutical ingredient cantharidin</description>
    <arm_group_label>Part A: Placebo</arm_group_label>
    <arm_group_label>Part B &amp; A: 24-hour-Placebo</arm_group_label>
    <arm_group_label>Part B &amp; A: 6-hour-Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Be healthy, immunocompetent males or females ≥ 18 years of age&#xD;
&#xD;
          -  Present with ≥ 2 and ≤ 30 external genital and/or perianal warts in ≥ 1 of the&#xD;
             following anatomic areas:&#xD;
&#xD;
               -  In both sexes: medial thigh (except inguinal fold); supra-pubic, perineal, and&#xD;
                  perianal areas&#xD;
&#xD;
               -  In men: over the glans penis (excluding urethral meatus), penis shaft, scrotum,&#xD;
                  and foreskin&#xD;
&#xD;
               -  In women: vulva (excluding labia minora and mucosal surfaces)&#xD;
&#xD;
          -  Have warts present for ≥ 4 weeks at the baseline visit&#xD;
&#xD;
          -  Have warts that are ≤ 8 mm in diameter each&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Have a wart within the allowed treatment area &gt; 8 mm in diameter or with an eroded or&#xD;
             ulcerated surface, in the Investigator's opinion&#xD;
&#xD;
          -  Have an unclear diagnosis of condyloma&#xD;
&#xD;
          -  Have any wart types other than genital warts (e.g., common or plantar warts) that&#xD;
             require treatment during the study period&#xD;
&#xD;
          -  Have active genital herpes eruption, or had active genital herpes lesions within 4&#xD;
             weeks before enrollment&#xD;
&#xD;
          -  Have a history of neoplasia or other HPV-associated malignancies within the last 5&#xD;
             years&#xD;
&#xD;
          -  Are systemically immunosuppressed&#xD;
&#xD;
          -  Are sexually active or may become sexually active and are unwilling to practice&#xD;
             responsible birth control methods&#xD;
&#xD;
          -  Are pregnant or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Guenthner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Indiana Clinical Trials Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Indiana Clinical Trials Center,PC</name>
      <address>
        <city>Plainfield</city>
        <state>Indiana</state>
        <zip>46168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DelRicht Research</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clarkston Skin Research</name>
      <address>
        <city>Clarkston</city>
        <state>Michigan</state>
        <zip>48346</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DelRicht Research</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 6, 2019</study_first_submitted>
  <study_first_submitted_qc>June 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2019</study_first_posted>
  <results_first_submitted>June 18, 2021</results_first_submitted>
  <results_first_submitted_qc>August 27, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 22, 2021</results_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Human Papilloma Virus (HPV)</keyword>
  <keyword>Genital Warts</keyword>
  <keyword>Sexually Transmitted Disease (STD)</keyword>
  <keyword>Viral Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infections</mesh_term>
    <mesh_term>Warts</mesh_term>
    <mesh_term>Sexually Transmitted Diseases</mesh_term>
    <mesh_term>Papillomavirus Infections</mesh_term>
    <mesh_term>Condylomata Acuminata</mesh_term>
    <mesh_term>Skin Diseases, Infectious</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Sexually Transmitted Diseases, Viral</mesh_term>
    <mesh_term>Skin Diseases, Viral</mesh_term>
    <mesh_term>Skin Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cantharidin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 7, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/22/NCT03981822/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 7, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/22/NCT03981822/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>2 groups from Part A were to be included in Part B based on Part A analysis.</recruitment_details>
      <pre_assignment_details>All subject numbers are based on ITT population. Participants in Part A 6-hour and 24-hour group were also included in Part B subject populations.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part A: VP-102 2-hour</title>
          <description>VP-102 and applicator: In part A, VP-102 will be applied for either 2, 6 or 24 hours with each regimen compared to placebo. For part B, 2 of the regimens from part A will be chosen for Part B with each compared to Placebo. Only 4 arms are actually being studied.</description>
        </group>
        <group group_id="P2">
          <title>Part A: VP-102 6-hour Group</title>
          <description>VP-102 and applicator: In part A, VP-102 will be applied for either 2, 6 or 24 hours with each regimen compared to placebo. For part B, 2 of the regimens from part A will be chosen for Part B with each compared to Placebo. Only 4 arms are actually being studied.</description>
        </group>
        <group group_id="P3">
          <title>Part A: VP-102 24-hour Group</title>
          <description>VP-102 and applicator: In part A, VP-102 will be applied for either 2, 6 or 24 hours with each regimen compared to placebo. For part B, 2 of the regimens from part A will be chosen for Part B with each compared to Placebo. Only 4 arms are actually being studied.</description>
        </group>
        <group group_id="P4">
          <title>Part A: Placebo</title>
          <description>This includes 3 subjects that received placebo (1 each for the 2-hour; 6-hour and 24-hour)</description>
        </group>
        <group group_id="P5">
          <title>Part B: VP-102 6-hour</title>
          <description>VP-102 and applicator: For part B, 2 of the regimens from part A will be chosen for Part B with each compared to Placebo. Only 4 arms are actually being studied.</description>
        </group>
        <group group_id="P6">
          <title>Part B: Placebo 6-hour</title>
          <description>Placebo and applicator: For part B, 2 of the regimens from part A will be chosen for Part B with each compared to Placebo. Only 4 arms are actually being studied.</description>
        </group>
        <group group_id="P7">
          <title>Part B: VP-102 24-hour</title>
          <description>VP-102 and applicator: For part B, 2 of the regimens from part A will be chosen for Part B with each compared to Placebo. Only 4 arms are actually being studied.</description>
        </group>
        <group group_id="P8">
          <title>Part B: Placebo 24-hour</title>
          <description>Placebo and applicator: For part B, 2 of the regimens from part A will be chosen for Part B with each compared to Placebo. Only 4 arms are actually being studied.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="25"/>
                <participants group_id="P6" count="23"/>
                <participants group_id="P7" count="22"/>
                <participants group_id="P8" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="17"/>
                <participants group_id="P6" count="17"/>
                <participants group_id="P7" count="16"/>
                <participants group_id="P8" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>COVID-19 Related</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>ITT population</population>
      <group_list>
        <group group_id="B1">
          <title>Part A: VP-102 2-hour</title>
          <description>VP-102 will be applied for 2-hours and removed. VP-102 is applied every 21 days for 4 treatments.</description>
        </group>
        <group group_id="B2">
          <title>Part A: VP-102 6-hour</title>
          <description>VP-102 will be applied for 6-hours and removed. VP-102 is applied every 21 days for 4 treatments.</description>
        </group>
        <group group_id="B3">
          <title>Part A: VP-102 24-hour</title>
          <description>VP-102 will be applied for 24-hours and removed. VP-102 is applied every 21 days for 4 treatments.</description>
        </group>
        <group group_id="B4">
          <title>Part A: Placebo</title>
          <description>Placebo will be applied for 2-,6- or 12-hours and removed. Placebo is applied every 21 days for 4 treatments.</description>
        </group>
        <group group_id="B5">
          <title>Part B: VP-102 6-hour</title>
          <description>VP-102 will be applied for 6-hours and removed. VP-102 is applied every 21 days for 4 treatments.</description>
        </group>
        <group group_id="B6">
          <title>Part B: 6-hour-Placebo</title>
          <description>Placebo will be applied for 6-hours and removed. VP-102 is applied every 21 days for 4 treatments.</description>
        </group>
        <group group_id="B7">
          <title>Part B: VP-102 24-hour</title>
          <description>VP-102 will be applied for 24-hours and removed. VP-102 is applied every 21 days for 4 treatments.</description>
        </group>
        <group group_id="B8">
          <title>Part B: 24-hour-Placebo</title>
          <description>Placebo will be applied for 24-hours and removed. VP-102 is applied every 21 days for 4 treatments.</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="3"/>
            <count group_id="B5" value="25"/>
            <count group_id="B6" value="23"/>
            <count group_id="B7" value="22"/>
            <count group_id="B8" value="17"/>
            <count group_id="B9" value="105"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.40" spread="9.915"/>
                    <measurement group_id="B2" value="43.00" spread="8.246"/>
                    <measurement group_id="B3" value="33.80" spread="5.263"/>
                    <measurement group_id="B4" value="32.00" spread="3.606"/>
                    <measurement group_id="B5" value="38.12" spread="10.138"/>
                    <measurement group_id="B6" value="35.87" spread="7.973"/>
                    <measurement group_id="B7" value="34.45" spread="7.526"/>
                    <measurement group_id="B8" value="33.88" spread="6.470"/>
                    <measurement group_id="B9" value="35.85" spread="8.260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="10"/>
                    <measurement group_id="B8" value="7"/>
                    <measurement group_id="B9" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="13"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="10"/>
                    <measurement group_id="B9" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="19"/>
                    <measurement group_id="B6" value="22"/>
                    <measurement group_id="B7" value="20"/>
                    <measurement group_id="B8" value="12"/>
                    <measurement group_id="B9" value="90"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="19"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="21"/>
                    <measurement group_id="B8" value="11"/>
                    <measurement group_id="B9" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="25"/>
                    <measurement group_id="B6" value="23"/>
                    <measurement group_id="B7" value="22"/>
                    <measurement group_id="B8" value="17"/>
                    <measurement group_id="B9" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline number of treatable external genital warts</title>
          <units>genital warts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7" spread="5.568"/>
                    <measurement group_id="B2" value="9.60" spread="12.012"/>
                    <measurement group_id="B3" value="13.00" spread="8.276"/>
                    <measurement group_id="B4" value="11.67" spread="12.423"/>
                    <measurement group_id="B5" value="8.28" spread="6.380"/>
                    <measurement group_id="B6" value="5.87" spread="3.684"/>
                    <measurement group_id="B7" value="8.68" spread="5.489"/>
                    <measurement group_id="B8" value="7.76" spread="6.897"/>
                    <measurement group_id="B9" value="8.08" spread="6.395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts at the Study Day 84 (End of Treatment) Visit.</title>
        <description>Proportion of subjects exhibiting complete clearance of all treatable warts (baseline and new) at the Study Day 84 EOT Visit.</description>
        <time_frame>Compares baseline wart count to Day 84, end of treatment.</time_frame>
        <population>Part B and A: Intent-to-Treat Population. Part B summary is pooled with its respective treatments from Part A.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B Pooled With Part A: VP-102 6-hour</title>
            <description>Data will be summarized for both Part B pooled with Part A for the applicable treatments.</description>
          </group>
          <group group_id="O2">
            <title>Part B Pooled With Part A: Placebo 6-hour</title>
            <description>Data will be summarized for both Part B pooled with Part A for the applicable treatments.</description>
          </group>
          <group group_id="O3">
            <title>Part B Pooled With Part A VP-102 24-hour</title>
            <description>Data will be summarized for both Part B pooled with Part A for the applicable treatments.</description>
          </group>
          <group group_id="O4">
            <title>Part B Pooled With Part A: Placebo 24-hour</title>
            <description>Data will be summarized for both Part B pooled with Part A for the applicable treatments.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts at the Study Day 84 (End of Treatment) Visit.</title>
          <description>Proportion of subjects exhibiting complete clearance of all treatable warts (baseline and new) at the Study Day 84 EOT Visit.</description>
          <population>Part B and A: Intent-to-Treat Population. Part B summary is pooled with its respective treatments from Part A.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0048</p_value>
            <p_value_desc>P-value is based on the CMH test stratified by gender.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0075</p_value>
            <p_value_desc>P-value is based on the CMH test stratified by gender.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)</title>
        <description>Proportion of subjects exhibiting complete clearance of all treatable warts (baseline and new) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, and Follow-up Visits on Study Day 112 and Study Day 147 (EOS).</description>
        <time_frame>Clearance compared from baseline to each study visit, treatment 2 (Day 21), 3 (Day 42), 4 (Day 63) and Day 84, 112 and 147.</time_frame>
        <population>Part B and A pooled - ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Part B Pooled With Part A: VP-102 6-hour</title>
            <description>Data will be summarized for both Part B pooled with Part A for the applicable treatments.</description>
          </group>
          <group group_id="O2">
            <title>Part B Pooled With Part A: Placebo 6-hour</title>
            <description>Data will be summarized for both Part B pooled with Part A for the applicable treatments.</description>
          </group>
          <group group_id="O3">
            <title>Part B Pooled With Part A VP-102 24-hour</title>
            <description>Data will be summarized for both Part B pooled with Part A for the applicable treatments.</description>
          </group>
          <group group_id="O4">
            <title>Part B Pooled With Part A: Placebo 24-hour</title>
            <description>Data will be summarized for both Part B pooled with Part A for the applicable treatments.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)</title>
          <description>Proportion of subjects exhibiting complete clearance of all treatable warts (baseline and new) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, and Follow-up Visits on Study Day 112 and Study Day 147 (EOS).</description>
          <population>Part B and A pooled - ITT population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Visit 2: Yes, Complete Clearance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Visit 3: Yes, Complete Clearance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Visit 4: Yes, Complete Clearance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Day 84 EOT: Yes, Complete Clearance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>F/U Visit Day 112: Yes, Complete Clearance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>F/U Visit Day 147: Yes, Complete Clearance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Visit 2 - Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3642</p_value>
            <p_value_desc>P-value is based on the CMH test stratified by gender.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Treatment Visit 2: Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0967</p_value>
            <p_value_desc>P-value is based on the CMH test stratified by gender.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Visit 3: Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0648</p_value>
            <p_value_desc>P-value is based on the CMH test stratified by gender.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Treatment Visit 3: Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1357</p_value>
            <p_value_desc>P-value is based on the CMH test stratified by gender.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Visit 4 Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0190</p_value>
            <p_value_desc>P-value is based on the CMH test stratified by gender. Part B summary is pooled with its respective treatments from</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Treatment Visit 4 Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0184</p_value>
            <p_value_desc>P-value is based on the CMH test stratified by gender.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Study Day 84 EOT Visit - Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0048</p_value>
            <p_value_desc>P-value is based on the CMH test stratified by gender.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Study Day 84 EOT Visit - Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0075</p_value>
            <p_value_desc>P-value is based on the CMH test stratified by gender.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Follow-up Visit Day 112 - Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0539</p_value>
            <p_value_desc>P-value is based on the CMH test stratified by gender.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Follow-up Visit Day 112 - Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1638</p_value>
            <p_value_desc>P-value is based on the CMH test stratified by gender.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Follow-up Visit Day 147 EOS - Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4766</p_value>
            <p_value_desc>P-value is based on the CMH test stratified by gender.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Follow-up Visit Day 147 EOS - Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1588</p_value>
            <p_value_desc>P-value is based on the CMH test stratified by gender.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects Exhibiting 90% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)</title>
        <description>Proportion of subjects exhibiting 90% clearance of all treatable warts (baseline and new) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS).</description>
        <time_frame>Compared from baseline to each study visit, treatment 2 (Day 21), 3 (Day 42), 4 (Day 63) and Day 84, 112 and 147.</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part B Pooled With Part A: VP-102 6-hour</title>
            <description>Data will be summarized for both Part B pooled with Part A for the applicable treatments.</description>
          </group>
          <group group_id="O2">
            <title>Part B Pooled With Part A: Placebo 6-hour</title>
            <description>Data will be summarized for both Part B pooled with Part A for the applicable treatments.</description>
          </group>
          <group group_id="O3">
            <title>Part B Pooled With Part A VP-102 24-hour</title>
            <description>Data will be summarized for both Part B pooled with Part A for the applicable treatments.</description>
          </group>
          <group group_id="O4">
            <title>Part B Pooled With Part A: Placebo 24-hour</title>
            <description>Data will be summarized for both Part B pooled with Part A for the applicable treatments.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects Exhibiting 90% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)</title>
          <description>Proportion of subjects exhibiting 90% clearance of all treatable warts (baseline and new) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS).</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Visit 2: Incidence of &gt;=90% Clearance: YES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Visit 3: Incidence of &gt;=90% Clearance: YES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Visit 4: Incidence of &gt;=90% Clearance: YES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Day 84 EOT: Incidence of &gt;=90% Clearance: YES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>F/U Visit Day 112: Incidence of &gt;=90% Clearance: YES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>F/U Visit Day 147: Incidence of &gt;=90% Clearance: YES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Visit 2 Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3642</p_value>
            <p_value_desc>P-value is based on the CMH test stratified by gender. Part B summary is pooled with its respective treatments from Part A.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Visit 3 Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0356</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>P-value is based on the CMH test stratified by gender.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Visit 4 Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0118</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>P-value is based on the CMH test stratified by gender</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Study Day84 EOT Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0026</p_value>
            <p_value_desc>P-value is based on the CMH test stratified by gender.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Follow-up Visit Day 112 Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0174</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>P-value is based on the CMH test stratified by gender.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Follow-up Visit Day 147 EOS Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1311</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>P-value is based on the CMH test stratified by gender.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Treatment Visit 2 Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0967</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>P-value is based on the CMH test stratified by gender.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Treatment Visit 3 Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1357</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>P-value is based on the CMH test stratified by gender.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Treatment Visit 4 Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0184</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>P-value is based on the CMH test stratified by gender.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Study Day 84 EOT Visit Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0024</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>P-value is based on the CMH test stratified by gender.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Follow-up Visit Day 112 Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1034</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>P-value is based on the CMH test stratified by gender.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Follow-up Visit Day 147 EOS Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1029</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>P-value is based on the CMH test stratified by gender.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects Exhibiting 75% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)</title>
        <description>Proportion of subjects exhibiting 75% clearance of all treatable warts (baseline and new) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS).</description>
        <time_frame>Compared from baseline to each study visit, treatment 2, (Day 21), 3 (Day 42), 4 (Day 63) and Day 84, 112 and 147.</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part B Pooled With Part A: VP-102 6-hour</title>
            <description>Data will be summarized for both Part B pooled with Part A for the applicable treatments.</description>
          </group>
          <group group_id="O2">
            <title>Part B Pooled With Part A: Placebo 6-hour</title>
            <description>Data will be summarized for both Part B pooled with Part A for the applicable treatments.</description>
          </group>
          <group group_id="O3">
            <title>Part B Pooled With Part A VP-102 24-hour</title>
            <description>Data will be summarized for both Part B pooled with Part A for the applicable treatments.</description>
          </group>
          <group group_id="O4">
            <title>Part B Pooled With Part A: Placebo 24-hour</title>
            <description>Data will be summarized for both Part B pooled with Part A for the applicable treatments.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects Exhibiting 75% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)</title>
          <description>Proportion of subjects exhibiting 75% clearance of all treatable warts (baseline and new) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS).</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Visit 2: Incidence of &gt;=75% Clearance: YES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Visit 3: Incidence of &gt;=75% Clearance: YES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Visit 4: Incidence of &gt;=75% Clearance: YES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Day 84 EOT: Incidence of &gt;=75% Clearance: YES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>F/U Visit Day 112: Incidence of &gt;=75% Clearance: YES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>F/U Visit Day 147: Incidence of &gt;=75% Clearance: YES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Visit 2: Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0356</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>P-value is based on the CMH test stratified by gender.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Treatment Visit 2: Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1477</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>P-value is based on the CMH test stratified by gender.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Visit 3: Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0062</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>P-value is based on the CMH test stratified by gender.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Treatment Visit 3: Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0046</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>P-value is based on the CMH test stratified by gender.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Visit 4: Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0177</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>P-value is based on the CMH test stratified by gender.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Treatment Visit 4: Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0054</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>P-value is based on the CMH test stratified by gender.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Study Day 84 (EOT) visit: Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0013</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>P-value is based on the CMH test stratified by gender.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Study Day 84 (EOT) Visit: Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0034</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>P-value is based on the CMH test stratified by gender.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Follow-up visit day 112: Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0156</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>P-value is based on the CMH test stratified by gender.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Follow-up visit day 112: Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0367</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>P-value is based on the CMH test stratified by gender.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Follow-up visit day 147 (EOS): Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1746</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>P-value is based on the CMH test stratified by gender.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Follow-up visit day 147 (EOS): Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0123</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>P-value is based on the CMH test stratified by gender.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)</title>
        <description>Change from baseline in the number of treatable warts (baseline and new) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS).&#xD;
Number of warts present were recorded at each treatment visit as well as follow-up visits. For each post baseline treatment visit, the change in number of warts from baseline was calculated.</description>
        <time_frame>Compared from baseline to each study visit, treatment 2 (Day 21), 3 (Day 42), 4 (Day 63) and Day 84, 112 and 147.</time_frame>
        <population>ITT Populations</population>
        <group_list>
          <group group_id="O1">
            <title>Part B Pooled With Part A: VP-102 6-hour</title>
            <description>Data will be summarized for both Part B pooled with Part A for the applicable treatments.</description>
          </group>
          <group group_id="O2">
            <title>Part B Pooled With Part A: Placebo 6-hour</title>
            <description>Data will be summarized for both Part B pooled with Part A for the applicable treatments.</description>
          </group>
          <group group_id="O3">
            <title>Part B Pooled With Part A VP-102 24-hour</title>
            <description>Data will be summarized for both Part B pooled with Part A for the applicable treatments.</description>
          </group>
          <group group_id="O4">
            <title>Part B Pooled With Part A: Placebo 24-hour</title>
            <description>Data will be summarized for both Part B pooled with Part A for the applicable treatments.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)</title>
          <description>Change from baseline in the number of treatable warts (baseline and new) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS).&#xD;
Number of warts present were recorded at each treatment visit as well as follow-up visits. For each post baseline treatment visit, the change in number of warts from baseline was calculated.</description>
          <population>ITT Populations</population>
          <units>Warts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Visit 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" spread="4.95"/>
                    <measurement group_id="O2" value="-0.3" spread="1.11"/>
                    <measurement group_id="O3" value="-5.3" spread="4.25"/>
                    <measurement group_id="O4" value="0.6" spread="30.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Visit 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.4" spread="5.80"/>
                    <measurement group_id="O2" value="-1.1" spread="3.69"/>
                    <measurement group_id="O3" value="-6.3" spread="5.45"/>
                    <measurement group_id="O4" value="-0.5" spread="5.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Visit 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.2" spread="4.72"/>
                    <measurement group_id="O2" value="-0.9" spread="3.98"/>
                    <measurement group_id="O3" value="-7.1" spread="5.09"/>
                    <measurement group_id="O4" value="0.5" spread="5.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Day 84 EOT Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.1" spread="5.24"/>
                    <measurement group_id="O2" value="-1.1" spread="4.92"/>
                    <measurement group_id="O3" value="-7.4" spread="6.37"/>
                    <measurement group_id="O4" value="0.1" spread="5.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow up Day 112</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.3" spread="5.21"/>
                    <measurement group_id="O2" value="-1.1" spread="5.33"/>
                    <measurement group_id="O3" value="-8.1" spread="5.54"/>
                    <measurement group_id="O4" value="-0.3" spread="4.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Visit Day 147 EOS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" spread="7.63"/>
                    <measurement group_id="O2" value="-1.2" spread="5.49"/>
                    <measurement group_id="O3" value="-7.9" spread="5.46"/>
                    <measurement group_id="O4" value="-0.1" spread="4.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Visit 2: Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0021</p_value>
            <p_value_desc>Analysis is based on MMRM model</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM model with gender, Tx, visit, Tx by visit interaction, and baseline wart count as factors.&#xD;
An unstructured covariance model was used.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>-3.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.41</ci_lower_limit>
            <ci_upper_limit>-1.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Visit 3: Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0150</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM model with gender, Tx, visit, treatment by visit interaction, and baseline wart count as factors.&#xD;
An unstructured covariance model was used.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>-4.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.95</ci_lower_limit>
            <ci_upper_limit>-0.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Visit 4: Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0011</p_value>
            <p_value_desc>Analysis is based on MMRM model</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM model with gender, Tx, visit, treatment by visit interaction, and baseline wart count as factors.&#xD;
An unstructured covariance model was used.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>-5.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.54</ci_lower_limit>
            <ci_upper_limit>-1.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Study Day 84 EOT Visit: Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0007</p_value>
            <p_value_desc>P-value is based on MMRM model</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM model with gender, Tx, visit, treatment by visit interaction, and baseline wart count as factors.&#xD;
An unstructured covariance model was used.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>-6.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.25</ci_lower_limit>
            <ci_upper_limit>-2.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Follow-up day 112: Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0012</p_value>
            <p_value_desc>P-value is based on MMRM model</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM model with gender, Tx, visit, treatment by visit interaction, and baseline wart count as factors.&#xD;
An unstructured covariance model was used.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>-6.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.50</ci_lower_limit>
            <ci_upper_limit>-1.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Follow-up visit day 147 (EOS): Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0349</p_value>
            <p_value_desc>P-value is based on MMRM model</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM model with gender, Tx, visit, treatment by visit interaction, and baseline wart count as factors.&#xD;
An unstructured covariance model was used.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>-5.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.78</ci_lower_limit>
            <ci_upper_limit>-0.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Treatment visit 2: Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value is based on MMRM mode</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM model with gender, Tx, visit, treatment by visit interaction, and baseline wart count as factors.&#xD;
An unstructured covariance model was used.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>-4.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.47</ci_lower_limit>
            <ci_upper_limit>-2.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Treatment Visit 3: Degrees of freedom associated with the error term were computed using Kenward-Rogers method.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0005</p_value>
            <p_value_desc>Analysis is based on MMRM model</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM model with gender, Tx, visit, treatment by visit interaction, and baseline wart count as factors.&#xD;
An unstructured covariance model was used.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>-6.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.37</ci_lower_limit>
            <ci_upper_limit>-2.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Treatment visit 4: Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Analysis based on MMRM model</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM model with gender, Tx, visit, treatment by visit interaction, and baseline wart count as factors.&#xD;
An unstructured covariance model was used.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>-6.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.65</ci_lower_limit>
            <ci_upper_limit>-4.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Study Day 84 (EOT): Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0004</p_value>
            <p_value_desc>Analysis is based on MMRM model</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM model with gender, Tx, visit, treatment by visit interaction, and baseline wart count as factors.&#xD;
An unstructured covariance model was used.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>-6.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.67</ci_lower_limit>
            <ci_upper_limit>-2.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Follow-up day 112: Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Analysis based on MMRM model</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM model with gender, Tx, visit, treatment by visit interaction, and baseline wart count as factors.&#xD;
An unstructured covariance model was used.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>-6.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.89</ci_lower_limit>
            <ci_upper_limit>-3.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Follow up day 147 (EOS): Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0005</p_value>
            <p_value_desc>Analysis based on MMRM model</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM model with gender, Tx, visit, treatment by visit interaction, and baseline wart count as factors.&#xD;
An unstructured covariance model was used.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>-6.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.20</ci_lower_limit>
            <ci_upper_limit>-2.94</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)</title>
        <description>Percent Change from Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS).</description>
        <time_frame>Percent change from baseline to each study visit, treatment 2 (Day 21), 3 (Day 42), 4 (Day 63) and Day 84, 112 and 147.</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part B Pooled With Part A: VP-102 6-hour</title>
            <description>Data will be summarized for both Part B pooled with Part A for the applicable treatments.</description>
          </group>
          <group group_id="O2">
            <title>Part B Pooled With Part A: Placebo 6-hour</title>
            <description>Data will be summarized for both Part B pooled with Part A for the applicable treatments.</description>
          </group>
          <group group_id="O3">
            <title>Part B Pooled With Part A VP-102 24-hour</title>
            <description>Data will be summarized for both Part B pooled with Part A for the applicable treatments.</description>
          </group>
          <group group_id="O4">
            <title>Part B Pooled With Part A: Placebo 24-hour</title>
            <description>Data will be summarized for both Part B pooled with Part A for the applicable treatments.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)</title>
          <description>Percent Change from Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS).</description>
          <population>ITT Population</population>
          <units>Wart percentage change from Baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Visit 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.4" spread="32.38"/>
                    <measurement group_id="O2" value="-6.2" spread="13.14"/>
                    <measurement group_id="O3" value="-58.5" spread="26.69"/>
                    <measurement group_id="O4" value="-2.6" spread="30.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Visit 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.0" spread="37.18"/>
                    <measurement group_id="O2" value="-8.9" spread="44.46"/>
                    <measurement group_id="O3" value="-69.3" spread="34.03"/>
                    <measurement group_id="O4" value="-17.8" spread="49.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Visit 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-65.8" spread="30.69"/>
                    <measurement group_id="O2" value="-5.1" spread="66.26"/>
                    <measurement group_id="O3" value="-77.3" spread="26.87"/>
                    <measurement group_id="O4" value="0.6" spread="41.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Day 84 End of Treatment Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-79.7" spread="34.27"/>
                    <measurement group_id="O2" value="-1.6" spread="78.34"/>
                    <measurement group_id="O3" value="-77.1" spread="38.66"/>
                    <measurement group_id="O4" value="-5.5" spread="47.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow up Day 112</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-68.2" spread="43.20"/>
                    <measurement group_id="O2" value="1.9" spread="91.11"/>
                    <measurement group_id="O3" value="-79.2" spread="28.36"/>
                    <measurement group_id="O4" value="-14.2" spread="49.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow up Visit Day 147 End of Study</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.5" spread="111.83"/>
                    <measurement group_id="O2" value="-6.0" spread="86.56"/>
                    <measurement group_id="O3" value="-79.6" spread="25.01"/>
                    <measurement group_id="O4" value="-12.9" spread="50.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Visit 2: Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value is based on MMRM model</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM model with gender, Tx, visit, treatment by visit interaction, and baseline wart count as factors.&#xD;
An unstructured covariance model was used.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>-41.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-51.31</ci_lower_limit>
            <ci_upper_limit>-20.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Visit 3: Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0004</p_value>
            <p_value_desc>P-value is based on MMRM model</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM model with gender, Tx, visit, treatment by visit interaction, and baseline wart count as factors.&#xD;
An unstructured covariance model was used.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>-50.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-66.18</ci_lower_limit>
            <ci_upper_limit>-19.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Visit 4: Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value is based on MMRM model</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM model with gender, Tx, visit, treatment by visit interaction, and baseline wart count as factors.&#xD;
An unstructured covariance model was used.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>-66.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-88.15</ci_lower_limit>
            <ci_upper_limit>-35.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Study Day 84 End of Treatment Visit: Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value is based on MMRM model</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM model with gender, Tx, visit, treatment by visit interaction, and baseline wart count as factors.&#xD;
An unstructured covariance model was used.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>-79.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-111.44</ci_lower_limit>
            <ci_upper_limit>-49.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Follow up Day 112: Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>P-value is based on MMRM model</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM model with gender, Tx, visit, treatment by visit interaction, and baseline wart count as factors.&#xD;
An unstructured covariance model was used.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>-69.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-103.17</ci_lower_limit>
            <ci_upper_limit>-35.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Follow up Visit Day 147 End of Study: Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1033</p_value>
            <p_value_desc>P-value is based on MMRM model</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM model with gender, Tx, visit, treatment by visit interaction, and baseline wart count as factors.&#xD;
An unstructured covariance model was used.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>-41.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-90.61</ci_lower_limit>
            <ci_upper_limit>8.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Treatment Visit 2: Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value is based on MMRM model</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM model with gender, Tx, visit, treatment by visit interaction, and baseline wart count as factors.&#xD;
An unstructured covariance model was used.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>-58.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-73.26</ci_lower_limit>
            <ci_upper_limit>-39.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Treatment Visit 3: Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value is based on MMRM model</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM model with gender, Tx, visit, treatment by visit interaction, and baseline wart count as factors.&#xD;
An unstructured covariance model was used.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>-69.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-81.61</ci_lower_limit>
            <ci_upper_limit>-28.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Treatment Visit 4: Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value is based on MMRM model with gender, treatment, visit, treatment by visit interaction, and baseline wart count as factors.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM model with gender, Tx, visit, treatment by visit interaction, and baseline wart count as factors.&#xD;
An unstructured covariance model was used.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>-76.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-107.19</ci_lower_limit>
            <ci_upper_limit>-45.61</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Study Day 84 End of Treatment Visit: Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0003</p_value>
            <p_value_desc>P-value is based on MMRM model with gender, treatment, visit, treatment by visit interaction, and baseline wart count as factors.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM model with gender, Tx, visit, treatment by visit interaction, and baseline wart count as factors.&#xD;
An unstructured covariance model was used.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>-74.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-102.96</ci_lower_limit>
            <ci_upper_limit>-31.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Follow-up Day 112: Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0004</p_value>
            <p_value_desc>P-value is based on MMRM model</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM model with gender, Tx, visit, treatment by visit interaction, and baseline wart count as factors.&#xD;
An unstructured covariance model was used.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>-77.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-110.32</ci_lower_limit>
            <ci_upper_limit>-32.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Follow-up Visit Day 147 End of Study: Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0178</p_value>
            <p_value_desc>P-value is based on MMRM model</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM model with gender, Tx, visit, treatment by visit interaction, and baseline wart count as factors.&#xD;
An unstructured covariance model was used.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>-77.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-120.82</ci_lower_limit>
            <ci_upper_limit>-11.88</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)</title>
        <description>Proportion of subjects exhibiting reduction of ≥ 1 treatable wart from baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS).</description>
        <time_frame>Compared from baseline to each study visit, treatment 2 (Day 21), 3 (Day 42), 4 (Day 63) and Day 84, 112 and 147.</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Part B Pooled With Part A: VP-102 6-hour</title>
            <description>Data will be summarized for both Part B pooled with Part A for the applicable treatments.</description>
          </group>
          <group group_id="O2">
            <title>Part B Pooled With Part A: Placebo 6-hour</title>
            <description>Data will be summarized for both Part B pooled with Part A for the applicable treatments.</description>
          </group>
          <group group_id="O3">
            <title>Part B Pooled With Part A VP-102 24-hour</title>
            <description>Data will be summarized for both Part B pooled with Part A for the applicable treatments.</description>
          </group>
          <group group_id="O4">
            <title>Part B Pooled With Part A: Placebo 24-hour</title>
            <description>Data will be summarized for both Part B pooled with Part A for the applicable treatments.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)</title>
          <description>Proportion of subjects exhibiting reduction of ≥ 1 treatable wart from baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS).</description>
          <population>ITT population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Visit 2</title>
              <category_list>
                <category>
                  <title>Yes - at least 1 wart reduction from Baseline</title>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Visit 3</title>
              <category_list>
                <category>
                  <title>Yes - at least 1 wart reduction from Baseline</title>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Visit 4</title>
              <category_list>
                <category>
                  <title>Yes - at least 1 wart reduction from Baseline</title>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Day 84 EOT Visit</title>
              <category_list>
                <category>
                  <title>Yes - at least 1 wart reduction from Baseline</title>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>F/U Visit Day 112</title>
              <category_list>
                <category>
                  <title>Yes - at least 1 wart reduction from Baseline</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>F/U Visit Day 147 EOS</title>
              <category_list>
                <category>
                  <title>Yes - at least 1 wart reduction from Baseline</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Visit 2: Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0004</p_value>
            <p_value_desc>P-value is based on the CMH test stratified by gender.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Treatment Visit 2: Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0005</p_value>
            <p_value_desc>P-value is based on the CMH test stratified by gender.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Visit 3: Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0698</p_value>
            <p_value_desc>P-value is based on the CMH test stratified by gender.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Treatment Visit 3: Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0100</p_value>
            <p_value_desc>P-value is based on the CMH test stratified by gender.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Visit 4: Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0101</p_value>
            <p_value_desc>P-value is based on the CMH test stratified by gender.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Treatment Visit 4: Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0077</p_value>
            <p_value_desc>P-value is based on the CMH test stratified by gender.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Study Day 84 EOT Visit: Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0640</p_value>
            <p_value_desc>P-value is based on the CMH test stratified by gender.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Study Day 84 EOT: Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0045</p_value>
            <p_value_desc>P-value is based on the CMH test stratified by gender.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Follow-up Visit Day 112: Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2840</p_value>
            <p_value_desc>P-value is based on the CMH test stratified by gender.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Follow-up Visit Day 112: Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0132</p_value>
            <p_value_desc>P-value is based on the CMH test stratified by gender.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Follow-up Visit Day 147 EOS: Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4668</p_value>
            <p_value_desc>P-value is based on the CMH test stratified by gender.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Follow-up Visit Day 147 EOS: Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0064</p_value>
            <p_value_desc>P-value is based on the CMH test stratified by gender.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Proportion of Subjects Who Are Clear at the Study Day 84 (End of Treatment) Visit and Remain Clear at the Follow-up Visits on Study Day 112 and Study Day 147 (End of Study)</title>
        <description>Proportion of subjects who are clear at all three study visits, Study Day 84 (End of Treatment) Visit and remain clear at the Follow-up Visits on Study Day 112 and Study Day 147 (End of Study).</description>
        <time_frame>Complete clearance compared from Day 84 to follow-up days 112 and 147.</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part B Pooled With Part A: VP-102 6-hour</title>
            <description>Data will be summarized for both Part B pooled with Part A for the applicable treatments.</description>
          </group>
          <group group_id="O2">
            <title>Part B Pooled With Part A: Placebo 6-hour</title>
            <description>Data will be summarized for both Part B pooled with Part A for the applicable treatments.</description>
          </group>
          <group group_id="O3">
            <title>Part B Pooled With Part A VP-102 24-hour</title>
            <description>Data will be summarized for both Part B pooled with Part A for the applicable treatments.</description>
          </group>
          <group group_id="O4">
            <title>Part B Pooled With Part A: Placebo 24-hour</title>
            <description>Data will be summarized for both Part B pooled with Part A for the applicable treatments.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects Who Are Clear at the Study Day 84 (End of Treatment) Visit and Remain Clear at the Follow-up Visits on Study Day 112 and Study Day 147 (End of Study)</title>
          <description>Proportion of subjects who are clear at all three study visits, Study Day 84 (End of Treatment) Visit and remain clear at the Follow-up Visits on Study Day 112 and Study Day 147 (End of Study).</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0364</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>Stratified by gender</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0215</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by gender</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in Total Wart Area (Sum of Individual Warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)</title>
        <description>Change from baseline in total wart area (sum of individual warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS).</description>
        <time_frame>Baseline to Study Day 84, Follow-up Visits at Days 112 and 147 (EOS)</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part B Pooled With Part A: VP-102 6-hour</title>
            <description>Data will be summarized for both Part B pooled with Part A for the applicable treatments.</description>
          </group>
          <group group_id="O2">
            <title>Part B Pooled With Part A: Placebo 6-hour</title>
            <description>Data will be summarized for both Part B pooled with Part A for the applicable treatments.</description>
          </group>
          <group group_id="O3">
            <title>Part B Pooled With Part A VP-102 24-hour</title>
            <description>Data will be summarized for both Part B pooled with Part A for the applicable treatments.</description>
          </group>
          <group group_id="O4">
            <title>Part B Pooled With Part A: Placebo 24-hour</title>
            <description>Data will be summarized for both Part B pooled with Part A for the applicable treatments.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Wart Area (Sum of Individual Warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)</title>
          <description>Change from baseline in total wart area (sum of individual warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS).</description>
          <population>ITT Population</population>
          <units>mm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Day 84 (EOT)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-52.60" spread="67.067"/>
                    <measurement group_id="O2" value="-23.64" spread="59.722"/>
                    <measurement group_id="O3" value="-72.87" spread="91.659"/>
                    <measurement group_id="O4" value="1.60" spread="33.796"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Day 112</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-79.43" spread="99.679"/>
                    <measurement group_id="O2" value="-20.35" spread="53.289"/>
                    <measurement group_id="O3" value="-82.79" spread="71.750"/>
                    <measurement group_id="O4" value="1.40" spread="39.963"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Visit Day 147 (EOS)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-59.28" spread="100.988"/>
                    <measurement group_id="O2" value="-6.02" spread="36.929"/>
                    <measurement group_id="O3" value="-68.78" spread="68.710"/>
                    <measurement group_id="O4" value="2.21" spread="45.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Study Day 84 (EOT: Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1222</p_value>
            <p_value_desc>Analysis is based on MMRM model</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM model with gender, Tx, visit, treatment by visit interaction, and baseline wart area as factors.&#xD;
An unstructured covariance model was used.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>-59.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-76.10</ci_lower_limit>
            <ci_upper_limit>9.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Study Day 112 (EOT: Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0403</p_value>
            <p_value_desc>Analysis based on MMRM model</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM model with gender, Tx, visit, treatment by visit interaction, and baseline wart area as factors.&#xD;
An unstructured covariance model was used.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>- 69.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-81.30</ci_lower_limit>
            <ci_upper_limit>-1.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Follow-up Visit Day 147 (EOS): Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0863</p_value>
            <p_value_desc>Analysis is based on MMRM model</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM model with gender, Tx, visit, treatment by visit interaction, and baseline wart area as factors.&#xD;
An unstructured covariance model was used.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>-58.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-77.79</ci_lower_limit>
            <ci_upper_limit>5.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Study Day 84 (EOT): Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0428</p_value>
            <p_value_desc>Analysis is based on MMRM model</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM model with gender, Tx, visit, treatment by visit interaction, and baseline wart area as factors.&#xD;
An unstructured covariance model was used.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>-62.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-100.76</ci_lower_limit>
            <ci_upper_limit>-1.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Follow-up Day 112: Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0084</p_value>
            <p_value_desc>Analysis is based on MMRM model</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM model with gender, Tx, visit, treatment by visit interaction, and baseline wart area as factors.&#xD;
An unstructured covariance model was used.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>-71.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-110.46</ci_lower_limit>
            <ci_upper_limit>-17.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Follow-up Visit Day 147 (EOS): Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0273</p_value>
            <p_value_desc>Analysis is based on MMRM model</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM model with gender, Tx, visit, treatment by visit interaction, and baseline wart area as factors.&#xD;
An unstructured covariance model was used.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>-63.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-103.08</ci_lower_limit>
            <ci_upper_limit>-6.35</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change From Baseline in the Total Wart Area (Sum of Individual Warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)</title>
        <description>Percent Change from baseline in the total wart area (sum of individual warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS).</description>
        <time_frame>Baseline to Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part B Pooled With Part A: VP-102 6-hour</title>
            <description>Data will be summarized for both Part B pooled with Part A for the applicable treatments.</description>
          </group>
          <group group_id="O2">
            <title>Part B Pooled With Part A: Placebo 6-hour</title>
            <description>Data will be summarized for both Part B pooled with Part A for the applicable treatments.</description>
          </group>
          <group group_id="O3">
            <title>Part B Pooled With Part A VP-102 24-hour</title>
            <description>Data will be summarized for both Part B pooled with Part A for the applicable treatments.</description>
          </group>
          <group group_id="O4">
            <title>Part B Pooled With Part A: Placebo 24-hour</title>
            <description>Data will be summarized for both Part B pooled with Part A for the applicable treatments.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in the Total Wart Area (Sum of Individual Warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)</title>
          <description>Percent Change from baseline in the total wart area (sum of individual warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS).</description>
          <population>ITT Population</population>
          <units>Change from baseline in % of wart area</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Day 84 (EOT)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-46.0" spread="52.77"/>
                    <measurement group_id="O2" value="-22.3" spread="57.92"/>
                    <measurement group_id="O3" value="-64.2" spread="55.78"/>
                    <measurement group_id="O4" value="-7.3" spread="93.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Day 112</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-48.2" spread="54.67"/>
                    <measurement group_id="O2" value="-21.5" spread="64.54"/>
                    <measurement group_id="O3" value="-76.4" spread="12.33"/>
                    <measurement group_id="O4" value="13.8" spread="129.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Day 147 (EOS)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-45.8" spread="71.37"/>
                    <measurement group_id="O2" value="-11.7" spread="52.52"/>
                    <measurement group_id="O3" value="-69.3" spread="16.44"/>
                    <measurement group_id="O4" value="19.9" spread="138.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Study Day 84 (EOT): Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Analysis is based on MMRM model</non_inferiority_desc>
            <p_value>0.3083</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM model with gender, Tx, visit, treatment by visit interaction, and baseline wart area as factors.&#xD;
An unstructured covariance model was used.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>- 44.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-69.96</ci_lower_limit>
            <ci_upper_limit>22.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Follow-up Day 112: Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1686</p_value>
            <p_value_desc>Analysis is based on MMRM model</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM model with gender, Tx, visit, treatment by visit interaction, and baseline wart area as factors.&#xD;
An unstructured covariance model was used.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>- 55.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-86.93</ci_lower_limit>
            <ci_upper_limit>15.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Follow-up Visit Day 147 End of Study: Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2384</p_value>
            <p_value_desc>Analysis is based on MMRM model</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM model with gender, Tx, visit, treatment by visit interaction, and baseline wart area as factors.&#xD;
An unstructured covariance model was used.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>- 38.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-87.04</ci_lower_limit>
            <ci_upper_limit>22.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Study Day 84 (EOT): Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0603</p_value>
            <p_value_desc>Analysis is based on MMRM model</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM model with gender, Tx, visit, treatment by visit interaction, and baseline wart area as factors.&#xD;
An unstructured covariance model was used.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>- 61.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-103.37</ci_lower_limit>
            <ci_upper_limit>2.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Follow-up Visit Day 112: Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0109</p_value>
            <p_value_desc>Analysis is based on MMRM model</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM model with gender, Tx, visit, treatment by visit interaction, and baseline wart area as factors.&#xD;
An unstructured covariance model was used.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>- 74.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-138.71</ci_lower_limit>
            <ci_upper_limit>-18.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Follow-up Visit Day 147 End of Study: Part B summary is pooled with its respective treatments from Part A.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0467</p_value>
            <p_value_desc>Analysis is base on MMRM model</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM model with gender, Tx, visit, treatment by visit interaction, and baseline wart area as factors.&#xD;
An unstructured covariance model was used.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>- 66.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-127.64</ci_lower_limit>
            <ci_upper_limit>-0.99</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events (AEs) were collected following the first application of study drug through Study Day 147.</time_frame>
      <desc>TEAEs defined as those AEs that occurred after dosing and those existing AEs that worsened during the study. Subject numbers in the AE summaries differ from the participant flow module based on the differences in the ITT population and the safety population. Due to randomization system errors, one subject was randomized to VP-102 6-hour but received VP-102 24-hour. Two subjects were randomized to Placebo 6-hour but received Placebo 24-hour.</desc>
      <group_list>
        <group group_id="E1">
          <title>Part B Pooled With Part A: VP-102 6-hour</title>
          <description>Data will be summarized for both Part B pooled with Part A for the applicable treatments.</description>
        </group>
        <group group_id="E2">
          <title>Part B Pooled With Part A: Placebo 6-hour</title>
          <description>Data will be summarized for both Part B pooled with Part A for the applicable treatments.</description>
        </group>
        <group group_id="E3">
          <title>Part B Pooled With Part A VP-102 24-hour</title>
          <description>Data will be summarized for both Part B pooled with Part A for the applicable treatments.</description>
        </group>
        <group group_id="E4">
          <title>Part B Pooled With Part A: Placebo 24-hour</title>
          <description>Data will be summarized for both Part B pooled with Part A for the applicable treatments.</description>
        </group>
        <group group_id="E5">
          <title>Part A: VP-102 2-hour</title>
          <description>Data summarized for VP-102 2-hour group.</description>
        </group>
        <group group_id="E6">
          <title>Part A: Placebo 2-hour</title>
          <description>Data summarized for VP-102 2-hour group..</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site vesicles</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Application site pain</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Application site scab</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Application site discolouration</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Application site dryness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Application site erosion</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Application site oedema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Application site exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Major Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vulvovaginal pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Umbilical hernia repair</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI is bound to terms and conditions of a Sponsored Clinical Trial Agreement which has strict confidentiality obligations running to Sponsor and broad provisions restricting PI's rights to publish or present any data or Study Results without Sponsor's express review consent and review.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to logistical and/or scheduling difficulties related to the SARS-CoV-2 (coronavirus-19; COVID-19) pandemic during the course of the study, six subjects discontinued due to COVID-19 related reasons.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Susan Cutler, VP, Medical Affairs</name_or_title>
      <organization>Verrica Pharmaceuticals</organization>
      <phone>484-773-0898</phone>
      <email>scutler@verrica.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

